Rayaldee: Uses, Dosage & Side Effects

What Is Rayaldee and What Is It Used For?

Rayaldee contains the active substance calcifediol, also known as 25-hydroxyvitamin D3 or calcidiol. Calcifediol is the main circulating form of vitamin D in the body and the immediate biochemical precursor of the active hormone calcitriol (1,25-dihydroxyvitamin D). In healthy individuals, vitamin D3 (cholecalciferol) is produced in the skin upon sunlight exposure or obtained from dietary sources. It is then converted in the liver to 25-hydroxyvitamin D3 (calcifediol) by the enzyme CYP2R1, and finally to the active hormone calcitriol in the kidneys by 1-alpha-hydroxylase (CYP27B1). Calcitriol binds to the vitamin D receptor (VDR) to regulate calcium and phosphate homeostasis, bone mineralization, and parathyroid gland function.

In chronic kidney disease (CKD), this carefully orchestrated system breaks down. As glomerular filtration declines, the kidneys lose the ability to adequately convert 25-hydroxyvitamin D into calcitriol. At the same time, CKD is associated with increased catabolism of vitamin D metabolites, rising fibroblast growth factor 23 (FGF-23) levels, and a relative deficiency of 25-hydroxyvitamin D in most patients. The result is a cascade of metabolic consequences known collectively as CKD-mineral and bone disorder (CKD-MBD), of which secondary hyperparathyroidism (SHPT) is a central feature. Persistent elevation of PTH contributes to bone disease (renal osteodystrophy), vascular calcification, cardiovascular morbidity, and increased mortality in CKD.

Rayaldee was developed specifically to address the 25-hydroxyvitamin D insufficiency that underlies SHPT in non-dialysis CKD. The product uses a proprietary modified-release matrix that releases calcifediol slowly over 24 hours. This pharmacokinetic profile is designed to produce a steady, dose-proportional rise in serum total 25-hydroxyvitamin D without the pronounced peaks and troughs seen with immediate-release calcifediol. The gradual increase in substrate availability supports 1-alpha-hydroxylation in the kidneys and in extrarenal tissues (including parathyroid cells themselves), increasing local calcitriol production. The result is a measured suppression of PTH secretion without the abrupt rises in serum calcium and phosphorus that often limit the use of active vitamin D analogs.

Rayaldee is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or stage 4 CKD (estimated glomerular filtration rate between 15 and 59 mL/min/1.73 m²) and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. The regulatory approval was based on two pivotal, identically designed, randomized, double-blind, placebo-controlled phase III trials that together enrolled 429 adults with stage 3 or 4 CKD, SHPT, and vitamin D insufficiency:

• Primary endpoint: Proportion of patients achieving at least a 30% reduction from baseline in plasma intact PTH (iPTH) during the final 6 weeks of a 26-week treatment period.
• Results: 33–34% of patients treated with Rayaldee reached the primary endpoint versus 7–8% on placebo, a statistically significant and clinically meaningful difference.
• Secondary endpoints: Rayaldee produced dose-dependent increases in serum total 25-hydroxyvitamin D into the normal range (30 ng/mL or above), while serum calcium, serum phosphorus, urinary calcium excretion, and fibroblast growth factor 23 (FGF-23) remained comparable to placebo.

Rayaldee was first approved by the U.S. Food and Drug Administration (FDA) in June 2016 and became commercially available in the United States in late 2016. It is distinct from nutritional vitamin D supplements (cholecalciferol or ergocalciferol) because it provides the already-hydroxylated metabolite, bypassing the first (hepatic) activation step and producing a far more predictable rise in serum 25-hydroxyvitamin D. It is also distinct from active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol) because it does not bypass the kidney; instead, it raises substrate for the kidney's own 1-alpha-hydroxylase, which is typically partially preserved in stage 3 and 4 CKD.

What Should You Know Before Taking Rayaldee?

Contraindications

Rayaldee is contraindicated in several clearly defined situations. You must not take Rayaldee if any of the following apply to you:

• Hypercalcemia: Serum calcium above the upper limit of normal (typically >10.2 mg/dL or 2.55 mmol/L). Raising vitamin D stores in the presence of hypercalcemia could precipitate serious complications.
• Evidence of vitamin D toxicity: Characterized by hypercalcemia, serum 25-hydroxyvitamin D above 100 ng/mL, hyperphosphatemia, and in severe cases soft tissue or vascular calcification.
• Known hypersensitivity: To calcifediol or to any of the excipients in the Rayaldee capsule, including any component of the modified-release matrix.

Warnings and Precautions

Before starting Rayaldee, your healthcare provider will obtain baseline laboratory measurements. Discuss the following with your doctor before beginning therapy:

• Adynamic bone disease: If iPTH is persistently below the upper limit of normal, treatment with Rayaldee may further suppress PTH and contribute to low-turnover bone disease. In general, active vitamin D therapy should not be used in patients with suppressed PTH.
• Digitalis toxicity: Hypercalcemia of any etiology potentiates the risk of digoxin toxicity. If you are taking digoxin or another cardiac glycoside, close monitoring of serum calcium and digoxin levels is essential.
• Nephrolithiasis (kidney stones): Any increase in urinary calcium could contribute to kidney stone formation. In clinical trials of Rayaldee, urinary calcium did not increase significantly compared with placebo, but caution is still advised in patients with a history of calcium-containing stones.
• Malabsorption syndromes: Conditions that impair fat absorption (such as cystic fibrosis, cholestatic liver disease, or extensive small-bowel resection) may reduce calcifediol absorption. In these patients, absorption from the extended-release matrix may be unpredictable.
• CYP-related interactions: Strong inducers of CYP24A1 (such as rifampin, phenytoin, phenobarbital, and carbamazepine) can accelerate the catabolism of 25-hydroxyvitamin D. Strong inhibitors of CYP3A (such as ketoconazole, itraconazole, clarithromycin, erythromycin, and certain HIV protease inhibitors) may reduce clearance and increase serum levels.

Required Laboratory Monitoring

Regular laboratory monitoring is a cornerstone of safe Rayaldee use. Your doctor will typically order the following at specific intervals:

Children and Adolescents

The safety and efficacy of Rayaldee have not been established in pediatric patients under 18 years of age. There are no clinical trial data to support its use in children or adolescents with chronic kidney disease, and dosing guidance is therefore not available. Management of SHPT in pediatric CKD typically involves specialist pediatric nephrology input, with treatment decisions guided by individual patient characteristics and by pediatric-specific guidelines.

Pregnancy and Breastfeeding

There are limited human data on the use of Rayaldee during pregnancy. Animal reproduction studies with calcifediol have demonstrated adverse effects on fetal development only at maternally toxic doses that produced significant hypercalcemia. Vitamin D and its metabolites cross the placenta, and fetal vitamin D levels are closely tied to maternal levels. Severe maternal hypercalcemia may be associated with supravalvular aortic stenosis and other developmental abnormalities in the fetus. If you are pregnant, think you may be pregnant, or are planning to become pregnant, discuss the risks and benefits of Rayaldee with your doctor. The decision to use Rayaldee during pregnancy must weigh maternal need for therapy against potential fetal risk.

Calcifediol is excreted in human breast milk. The amount of calcifediol in breast milk correlates with maternal 25-hydroxyvitamin D levels. Infants of mothers taking Rayaldee could potentially be exposed to supraphysiologic levels of 25-hydroxyvitamin D, with theoretical risks of hypercalcemia. If treatment with Rayaldee is necessary during lactation, monitoring of the infant for signs of hypercalcemia (poor feeding, vomiting, failure to thrive, irritability) is recommended, along with regular monitoring of maternal serum calcium.

Elderly Patients

No overall differences in safety or efficacy were observed between older (65 years and over) and younger patients in clinical trials. Because elderly patients with CKD often have multiple comorbidities, take multiple concomitant medications, and may have altered drug handling, individualized monitoring is advisable. Starting at the standard dose of 30 mcg once daily at bedtime and titrating based on laboratory response is appropriate.

Driving and Operating Machinery

Rayaldee has not been shown to affect the ability to drive or operate machinery. No specific studies have been performed, but based on its pharmacology and the known side effect profile, impairment is unlikely. However, symptomatic hypercalcemia (if it occurs) can cause fatigue, confusion, or weakness, and in that situation you should refrain from driving and seek medical advice.

How Does Rayaldee Interact with Other Drugs?

Because calcifediol is partially metabolized by hepatic and renal cytochrome P450 enzymes and because its pharmacodynamic effect involves the regulation of serum calcium, Rayaldee can interact with several drug classes. The interactions below are clinically relevant and should be discussed with your healthcare provider before starting therapy.

Major Interactions

The following interactions require either avoidance of the combination, careful monitoring, or dose adjustments of one or both drugs.

Minor Interactions and Special Considerations

A number of medications commonly co-prescribed in CKD may also interact in more subtle ways with Rayaldee:

• Phosphate binders (sevelamer, lanthanum, calcium-based binders, iron-based binders): These are commonly used in CKD to control hyperphosphatemia. No specific pharmacokinetic interaction has been established with Rayaldee, but calcium-based binders contribute to the total calcium load. Monitoring of serum calcium and phosphorus remains essential.
• Cinacalcet / etelcalcetide (calcimimetics): Calcimimetics lower PTH through a mechanism distinct from vitamin D therapy. Combining a vitamin D prohormone with a calcimimetic may be appropriate in selected patients, but usually in nephrology specialist care with careful PTH monitoring.
• Loop diuretics (furosemide, bumetanide): Loop diuretics increase urinary calcium excretion, which may reduce the hypercalcemic risk associated with vitamin D therapy. No specific dose adjustment is required.
• Corticosteroids: Glucocorticoids can antagonize the calcemic effect of vitamin D and accelerate its metabolism. Patients on long-term corticosteroids may require slightly higher doses of Rayaldee to achieve target 25-hydroxyvitamin D levels.
• Magnesium-containing antacids: Use with vitamin D products may, in theory, increase the risk of hypermagnesemia, particularly in patients with reduced kidney function. Avoid routine use of magnesium-containing antacids in advanced CKD.

What Is the Correct Dosage of Rayaldee?

Rayaldee should always be used exactly as your doctor has prescribed. The goal of therapy is to raise serum total 25-hydroxyvitamin D above 30 ng/mL while lowering intact PTH toward the target range recommended by current guidelines (such as KDIGO), without producing hypercalcemia, hyperphosphatemia, or hypervitaminosis D. Because calcifediol is a lipophilic compound and steady-state levels take months to reach, dose adjustments should be made gradually and based on laboratory data rather than symptoms.

Adults

The initial dose and titration regimen in adults with stage 3 or 4 CKD and vitamin D insufficiency is as follows:

*Before increasing to 60 mcg, the following laboratory criteria should be met: serum calcium below 9.8 mg/dL (2.44 mmol/L), serum phosphorus below 5.5 mg/dL (1.78 mmol/L), and serum total 25-hydroxyvitamin D below 100 ng/mL (249.6 nmol/L).

Rayaldee capsules should be swallowed whole with water. Do not crush, chew, open, or break the capsules, because doing so would disrupt the extended-release matrix and eliminate the controlled delivery that is central to the product's efficacy and tolerability profile. Bedtime administration was used in clinical trials and is the recommended timing; whether Rayaldee is taken with or without food does not substantially affect its absorption, but consistency is sensible.

Children and Adolescents

Rayaldee is not indicated for use in patients under 18 years of age. The safety and efficacy of calcifediol extended-release capsules have not been established in pediatric patients. Children and adolescents with CKD-mineral and bone disorder should be managed by specialists in pediatric nephrology, using therapies with established pediatric safety profiles.

Elderly Patients

Patients aged 65 years and older represented a substantial proportion of the population in the phase III trials, reflecting the epidemiology of CKD. No age-based dose adjustment is required, and efficacy and safety in older adults were comparable to those in younger adults. As in any older population, concomitant medications and comorbidities should be reviewed carefully.

Renal and Hepatic Impairment

Rayaldee is indicated specifically for use in stage 3 and stage 4 CKD; the drug has not been studied in patients with stage 5 CKD who are not on dialysis, nor in dialysis-dependent patients, and it is not indicated in these populations. In patients with hepatic impairment, no specific dose adjustment is established, but because 1-alpha-hydroxylation is primarily renal rather than hepatic, dosing considerations mirror those for the target CKD population. Clinical judgement and laboratory monitoring are especially important in patients with coexisting hepatic dysfunction.

Missed Dose

If you forget to take your Rayaldee capsule at bedtime, take it as soon as you remember. However, if it is already close to the time of your next dose, skip the missed dose and resume your normal schedule. Do not take a double dose to make up for a missed one. Because Rayaldee has a half-life of approximately 11 days, a single missed dose is unlikely to materially affect your 25-hydroxyvitamin D levels. Consistent dosing is more important over time than any single missed tablet.

Overdose

Chronic overdose or excessive cumulative exposure to vitamin D metabolites can result in hypervitaminosis D, which is characterized by hypercalcemia, hypercalciuria, hyperphosphatemia, and, in severe cases, soft tissue and vascular calcification. Symptoms of hypercalcemia include nausea, vomiting, abdominal pain, constipation, polyuria, polydipsia, weakness, fatigue, confusion, and, in severe cases, cardiac arrhythmias. If you suspect an overdose of Rayaldee, contact your healthcare provider or poison control center immediately. Management includes discontinuing Rayaldee, any calcium supplements, and other vitamin D products; increasing hydration; instituting a low-calcium diet; and, if necessary, using medications such as loop diuretics, glucocorticoids, calcitonin, or bisphosphonates to lower serum calcium. Because of the long half-life of calcifediol, recovery from overdose may take weeks, and prolonged monitoring is warranted.

How to Take Rayaldee

To ensure Rayaldee works as intended and side effects are minimized, follow these practical instructions:

1. Take once daily at bedtime: Consistent timing helps maintain steady 25-hydroxyvitamin D levels and is the pattern used in clinical trials.
2. Swallow whole: Do not crush, chew, split, or open the capsule. The extended-release matrix releases calcifediol over approximately 24 hours; damaging the capsule produces an immediate-release effect.
3. Take with or without food: Food has minimal effect on absorption, but being consistent from day to day is sensible.
4. Space from bile acid sequestrants: If you take cholestyramine, colestipol, colesevelam, or similar medications, take Rayaldee at least 1 hour before or 4-6 hours after the sequestrant.
5. Do not stop abruptly: If you want to discontinue Rayaldee, discuss this with your doctor. Suddenly stopping may lead to PTH rising again over subsequent months.
6. Keep all laboratory appointments: Monitoring of serum calcium, phosphorus, 25-hydroxyvitamin D, and PTH is the only reliable way to confirm that treatment is working safely.

What Are the Side Effects of Rayaldee?

Like all medicines, Rayaldee can cause side effects, although not everyone will experience them. The adverse event profile comes primarily from two 26-week, placebo-controlled phase III trials in adults with stage 3 or 4 CKD and SHPT, supplemented by open-label extension data and post-marketing experience. In clinical trials, the overall discontinuation rate due to adverse events was modest and comparable between Rayaldee and placebo, reflecting a generally acceptable tolerability profile.

A key strength of Rayaldee's profile is that, despite effectively raising 25-hydroxyvitamin D and lowering PTH, it did not produce statistically meaningful increases in the mineral metabolism parameters that often limit active vitamin D analogs. Serum calcium, serum phosphorus, urinary calcium excretion, and FGF-23 were comparable between Rayaldee-treated patients and those on placebo in pivotal studies.

It is important to put the side effect profile in clinical context. Many of the events categorized as very common or common (anemia, cough, congestive heart failure, hyperkalemia) reflect the natural course of advanced CKD rather than effects specific to Rayaldee. In placebo-controlled studies, most of these events occurred at similar rates in placebo-treated patients. In contrast, adverse effects more directly attributable to the pharmacology of calcifediol, such as hypercalcemia, hyperphosphatemia, and hypercalciuria, were uncommon at the approved doses and were managed with temporary dose interruptions or reductions when they occurred.

In the long-term extension studies, the safety profile of Rayaldee remained consistent with the pivotal trials; no new safety signals emerged with up to 1 year of continuous treatment. Importantly, there was no evidence that sustained elevation of 25-hydroxyvitamin D into the target range (40-60 ng/mL) was associated with progressive mineral metabolism disturbance when combined with appropriate monitoring.

How Should You Store Rayaldee?

Correct storage of Rayaldee helps maintain the stability of calcifediol within the extended-release matrix and preserves the integrity of the soft gelatin capsule. Follow these storage recommendations:

• Room temperature storage: Store at 20-25 °C (68-77 °F), with excursions permitted between 15-30 °C (59-86 °F). There is no need to refrigerate Rayaldee, and freezing should be avoided.
• Original container: Keep capsules in the bottle or blister pack in which they were dispensed. The container is designed to protect the soft gelatin capsules from moisture and light.
• Protect from light and humidity: Do not store Rayaldee in bathrooms or other humid areas. Avoid exposing the capsules to direct sunlight or high temperatures (for example, near radiators, stoves, or in a hot car).
• Keep out of reach of children: Like all vitamin D products, Rayaldee should be stored safely. Accidental ingestion by a child could cause hypercalcemia and vitamin D toxicity.
• Check expiration date: Do not use Rayaldee after the expiration date printed on the container or carton. The expiration date refers to the last day of that month.
• Visual inspection: Each capsule should appear intact, without signs of leakage, discoloration, or brittleness. Do not use a capsule that has been damaged or has clearly been exposed to extreme conditions.
• Disposal of unused medication: Do not dispose of Rayaldee in household waste or flush it down the toilet. Ask your pharmacist how to dispose of unused medications safely, or use an approved take-back program where available.

When traveling, carry Rayaldee in its original container in your hand luggage rather than checked baggage, where extreme temperatures in the cargo hold could compromise the product. Keep the prescription label visible and bring documentation of your prescription if you are traveling internationally. Most airport security scanners are safe for oral medications.

What Does Rayaldee Contain?

Understanding the composition of your medication is especially important if you have allergies, sensitivities, or specific dietary restrictions. Below is an overview of the active and inactive ingredients in Rayaldee.

Active Ingredient

The active substance is calcifediol (also called 25-hydroxyvitamin D3 or calcidiol), a naturally occurring circulating metabolite of vitamin D3. Each Rayaldee soft gelatin capsule contains 30 micrograms (mcg) of calcifediol.

Inactive Ingredients (Excipients)

Appearance and Pack Sizes

Rayaldee is supplied as an oval, soft gelatin capsule with a distinctive color and identifying imprint. Each capsule contains 30 mcg of calcifediol in an oily extended-release matrix. Rayaldee is typically dispensed in high-density polyethylene (HDPE) bottles containing 30 capsules, providing approximately one month of therapy at the starting dose. Availability of alternative pack sizes may vary by country and pharmacy.

Marketing Authorization Holder and Manufacturer

Rayaldee is developed and marketed by OPKO Health, Inc. and its subsidiary OPKO Renal. The product is manufactured by Eirgen Pharma Ltd. (Waterford, Ireland). Rayaldee was first approved by the U.S. Food and Drug Administration (FDA) in June 2016. Availability in other jurisdictions is subject to local regulatory approval; Rayaldee is distributed under licensing arrangements with regional pharmaceutical partners in selected international markets. Consult your local prescribing information and regulatory authority for country-specific details.